KAPA.US Kairos Pharma, Ltd.
- Market cap
- USD 1.54M
- P/E
- -
- P/B
- 0.37x
- ROE
- -172.9%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is KAPA.US undervalued?
Graham numberThe Graham number of Kairos Pharma, Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Kairos Pharma, Ltd. fundamental analysis
No fundamental analysis for Kairos Pharma, Ltd. yet.
Kairos Pharma, Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinic…
Full company profileKairos Pharma, Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Kairos Pharma, Ltd. annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Gross Profit | - | -98.0K | -160K | -160K | -160K | - | - |
| Operating Income | -1.05M | -1.94M | -571K | -1.71M | -2.34M | -5.57M | -6.72M |
| EBITDA | -1.05M | -1.85M | -411K | -1.55M | -1.58M | -5.29M | -6.65M |
| Net Income | -1.05M | -2.15M | -1.05M | -1.81M | -2.60M | -5.45M | -6.70M |
| EPS | -0.66 | -1.17 | -0.72 | -1.22 | -1.60 | -2.07 | -2.00 |
| Balance Sheet | |||||||
| Total Assets | 14.3K | 775K | 1.04M | 965K | 5.77M | 6.54M | 4.37M |
| Total Liabilities | 357K | 1.94M | 2.22M | 3.04M | 992K | 199K | 495K |
| Shareholders' Equity | -343K | -1.17M | -1.18M | -2.08M | 4.78M | 6.34M | 3.88M |
| Cash & Short-term Investments | 14.3K | 73.0K | 437K | 93.0K | 1.27M | 4.49M | 3.13M |
| Total Debt | 50.0K | 380K | 586K | 638K | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -38.5K | -412K | -353K | 81.0K | -3.96M | -3.44M | -4.04M |
| Capital Expenditure | 5.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -38.5K | -412K | -353K | 81.0K | -3.96M | -3.44M | -4.04M |
| Ratios | |||||||
| ROE | - | - | - | - | -54.5% | -85.9% | -172.9% |
| ROA | -7,348.0% | -276.8% | -101.4% | -187.8% | -45.1% | -83.3% | -153.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
Kairos Pharma, Ltd. dividends
Kairos Pharma, Ltd. has not paid dividends in the last 6 fiscal years.
Last stock split: 1:7 on Sep 1, 2026.
Who owns Kairos Pharma, Ltd.
- Insiders 33.64%
- Institutions 6.56%
- Public & others 59.80%
- Shares outstanding 3.39M
- Free float 2.25M
Kairos Pharma, Ltd. company profile
- Company name
- Kairos Pharma, Ltd.
- Ticker
- KAPA.US
- Exchange
- USA Stocks
- Listed since
- Sep 16, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 1
- Fiscal year end
- December
- Address
- 2355 Westwood Blvd., Los Angeles, CA, United States, 90064
- Phone
- 310 948 2356
- Website
- kairospharma.com
About Kairos Pharma, Ltd.
Kairos Pharma, Ltd., a clinical-stage biopharmaceutical company, develops immunotherapy and cell therapies for the treatment of cancer. The company offers therapeutics, including antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. It also develops ENV 105, an antibody therapeutic that is in a Phase 2 clinical trial for prostate cancer patients resistant to androgen-targeted therapy, as well as in a Phase 1 clinical trial for non-small cell lung cancer. In addition, the company's products under the preclinical stage include KROS 201 that activates T cells using dendritic cells for the treatment of patients with glioblastoma; KROS 101, an orally available glucocorticoid-induced tumor necrosis factor receptor (GITR) ligand small-molecule antagonist designed to deplete regulatory T cells (Tregs) and activate effector T cells to augment the antitumor immune response for the treatment of patients with cancer, as well as a systemic immune modulator to address immunosuppressive activity of solid cancers; KROS 102, a GITR antagonist to increase the inhibitory regulatory Tregs functions for the treatment of autoimmune disease; KROS 301, a tumor-targeting small molecule and checkpoint inhibitor that targets tumor cells in RelA/p65 biomarker-positive solid tumors for the treatment of triple-negative breast cancer; KROS 401, a tumor microenvironment immune modulator and cyclic peptide inhibitor of IL-4 and IL-13, reversing tumor associated macrophage inhibition that blocks the IL4/IL13 cytokine immune receptors for the treatment of triple-negative breast cancer; and ENV 205, an antibody fragment that targets mitochondrial DNA for the treatment of prostate cancer. The company also develops ENV-105 (carotuximab). The company was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. Kairos Pharma, Ltd. was incorporated in 2013 and is based in Los Angeles, California.
Kairos Pharma, Ltd. management
4- Dr. John S. Yu M.D., Ph.D.CEO, Chairman & Secretary · born 1964
- Mr. Douglas W. Samuelson CPAChief Financial Officer · born 1960
- Dr. Neil A. Bhowmick Ph.D.Chief Scientific Officer · born 1970
- Dr. Ramachandran Murali Ph.D.Vice President of Research & Development · born 1960